

L2 ANSWER 10 OF 10 DGENE COPYRIGHT 2006 The Thomson Corp on STN

ACCESSION NUMBER: AAY95896 Peptide DGENE

TITLE: Regulating mucus secretion by a mucus-secreting cell, useful for treating e.g. bronchitis, asthma or pneumonia, by administering a compound that inhibits or enhances myristolated alanine-rich C-kinase substrate protein -

INVENTOR: Li Y; Martin L D; Adler K B

PATENT ASSIGNEE: (UYNC-N)UNIV NORTH CAROLINA STATE.

PATENT INFO: WO 2000050062 A2 20000831 66

APPLICATION INFO: WO 2000-US5050 20000224

PRIORITY INFO: US 1999-256154 19990224

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-572036 [53]

DESCRIPTION: MANS peptide inhibitor of MARCKS-related mucus secretion.

AB The present sequence is that of MANS peptide, comprising the N-terminal region of human myristoylated alanine-rich C kinase substrate MARCKS protein (see AAY95898), a major cellular substrate for protein kinase S. MANS peptide inhibits secretion of mucus from mucus membranes and mucus-secreting cells, including human airway epithelial cells. It is suggested to block attachment of MARCKS protein to the mucin granule, thus blocking or inhibiting the release of mucin granules and the secretion of mucus by the cell. The invention relates to methods and compounds for decreasing mucus secretion, particularly in the airways. Such compounds include MANS peptide and antisense oligonucleotides to MARCKS. They are useful in inhibiting mucus secretion in conditions such as bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, asthma, emphysema, pneumonia, influenza, rhinitis and the common cold.

DESC MANS peptide inhibitor of MARCKS-related mucus secretion.

AB The present sequence is that of MANS peptide, comprising the N-terminal region of human myristoylated alanine-rich C kinase substrate MARCKS protein (see AAY95898), a major cellular substrate for protein kinase S. MANS peptide inhibits secretion of mucus from mucus membranes and mucus-secreting cells, including human airway epithelial cells. It is suggested to block attachment of MARCKS protein to the mucin granule, thus blocking or inhibiting the release of mucin granules and the secretion of mucus by. . . the cell. The invention relates to methods and compounds for decreasing mucus secretion, particularly in the airways. Such compounds include MANS peptide and antisense oligonucleotides to MARCKS. They are useful in inhibiting mucus secretion in conditions such as bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, asthma, emphysema, . . .